Constitutive coupling of a chimeric dopamine D2/α1B receptor to the phospholipase C pathway: Inverse agonism to silent antagonism by neuroleptic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 1, 2003, Pages 380-390

  Wurch, Thierry ^a   Boutet Robinet, Elisa A ^a   Palmier, Christiane ^a   Colpaert, Francis C ^a   Pauwels, Petrus J ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 5 METHOXY 1 METHYL 2 (DI PROPYLAMINOTETRALIN); ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; BROMERGURIDE; BROMOCRIPTINE; BUTACLAMOL; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; FLUPHENAZINE; HALOPERIDOL; INOSITOL PHOSPHATE; LIGAND; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHOLIPASE C; PRAZOSIN; RACLOPRIDE; RISPERIDONE; SULPIRIDE; TROPAPRIDE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ARTICLE; CHIMERA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; LIGAND BINDING; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; CALCIUM; CHO CELLS; CRICETINAE; DIGITONIN; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INOSITOL PHOSPHATES; KINETICS; LIGANDS; PHOSPHOLIPASE C; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 0037214555     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.040535     Document Type: Article

References (34)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
2. Bullock CM, Li C, Li M, Bermak JC, and Zhou QY (2001) Sensitization of adenylate cyclase induced by a dopamine D2 receptor mutant: Inverse agonism by D2 receptor antagonists. Prog Neuropsychopharmacol Biol Psychiatry 25:1387-1402.
3. Burstein ES, Spalding TA, and Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319.
4. 2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127:1135-1144.
5. Eason MG and Liggett SB (1996) Chimeric mutagenesis of putative G-protein coupling domains of the α2A-adrenergic receptor. Localization of two redundant and fully competent Gi coupling domains. J Biol Chem 271:12826-12832.
6. Hall DA and Strange PG (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol 121:731-736.
7. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133.
8. Jewell-Motz EA, Donnelly ET, Eason MG, and Liggett SB (1998) Agonist-mediated down-regulation of Gαi via the α2-adrenergic receptor is targeted by receptor-Gi interaction and is independent of receptor signaling and regulation. Biochemistry 37:15720-15725.
9. Jewell-Motz EA, Small KM, Theiss CT, and Liggett SB (2000) α2A/α2C-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation. J Biol Chem 275:28989-28993.
10. Kenakin T (1997) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
11. Kenakin T (2001) Inverse, protean and ligand-selective agonism: Matters of receptor conformation. FASEB J 15:598-611.
12. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, and Lefkowitz RJ (1992) Constitutive activation of the α1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
13. Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, and Lefkowitz RJ (1988) Chimeric α2-, β2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science (Wash DC) 240:1310-1316.
14. Kozell LB and Neve KA (1997) Constitutive activity of a chimeric D2/D1 dopamine receptor. Mol Pharmacol 52:1137-1149.
15. Lahti AC, Weiler M, Carlsson A, and Tamminga CA (1998) Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 105:719-734.
16. Liggett SB (1991) Desensitization of the beta-adrenergic receptor: Distinct molecular determinants of phosphorylation by specific kinases. Pharmacol Res 24 (Suppl 1):29-41.
17. 2 receptors? J Neural Transm 92:213-220.
18. Nilsson CL, Ekman A, Hellstrand M, and Eriksson E (1996) Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride and phenoxybenzamine. Neuropsychopharmacology 15:53-61.
19. 2+ mobilizing agent. Br J Pharmacol 124:1651-1658.
20. 2short receptor: Dopamine-bound versus antagonist-bound receptor states. J Pharmacol Exp Ther 297:133-140.
21. 2short receptor by partial agonists in a G protein-dependent manner. Biochem Pharmacol 62:723-732.
22. αo protein coexpression: Evidence for inverse agonism. J Pharmacol Exp Ther 292: 654-663.
23. 2long receptor upon modulation of its activation state. Br J Pharmacol 134:88-97.
24. Pauwels PJ and Wurch T (1998) Amino acid domains involved in constitutive activation of G protein-coupled receptors: A target for inverse agonists. Mol Neurobiol 17:109-136.
25. 1B-adrenergic receptor: Role of highly conserved polar amino acids in receptor activation. EMBO (Eur Mol Biol Organ) J 15:3566-3578.
26. 1B-adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate. Proc Natl Acad Sci USA 94:808-813.
27. Schutz W and Freissmuth M (1992) Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol Sci 13:376-380.
28. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness M, Parry-Smith DJ, et al. (1995) Cloning and pharmacological characterization of human α-1 adrenergic receptors: Sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther 272:134-142.
29. Strange PG (2001) Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119-133.
30. Strange PG (2002) Mechanisms of inverse agonism at G protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
31. Wieland T, Liedel K, Kaldenberg-Stasch S, Meyer zu Heringdorf D, Schmidt M, and Jakobs KH (1995) Analysis of receptor-G protein interaction in permeabilized cells. Naunyn-Schmiedeberg's Arch Pharmacol 351:329-336.
32. 2 dopamine receptor that adopts the activated conformation. J Neurochem 77:493-504.
33. 2A adrenergic receptors. Br J Pharmacol 126: 939-948.
34. Wurch T, Lestienne F, and Pauwels PJ (1998) A modified overlap extension PCR method to create chimaeric genes in the absence of restriction sites. Biotechnol Tech 12:653-657.